When Canadian researchers asked HIV-positive people over the age of 50 how they would define “successful ageing”, six key themes emerged – accepting limitations, staying positive, maintaining social support, taking responsibility, living a healthy lifestyle, and engaging in meaningful activities.
Writing in the International Journal of STD ...
America House Kyiv is pleased to announce a call for artists for an exhibit “B POSITIVE.” The “B POSITIVE” exhibit supports the 2017 “Positive Life” campaign organized by Small Heart with Art, in partnership with the East Europe & Central Asia Union of PWLH.
This exhibit will ...
In Chisinau, at the annual coordination meeting of the Participants of the General Meeting of the ECUO, the priorities for advocacy activities for the coming year were identified.
The ECUO participants and focal points from 15 countries of the Eastern Europe and Central Asia, as well ...
Northwestern Medicine scientists have developed a novel method of tracking HIV infection, allowing the behavior of individual virions — infectious particles — to be connected to infectivity.
The findings, published in Proceedings of the National Academy of Sciences, could help lead to the development of novel therapies for HIV ...
President of the ECUO Vladimir Zhovtyak talks, in his blog, about the main issues to be discussed at the working meeting of the ECUO communities, which will be held on the 6th of September in Poland.
During the first working week of autumn, representatives of ECUO ...
One of the most critical scientific questions in TB today is the optimal combination of new and repurposed drugs for the treatment of extensively drug-resistant, pre- extensively drug-resistant, and hard-to-treat multidrug-resistant TB (XDR-TB, pre-XDR-TB, MDR-TB).
Тhe Global TB Community Advisory Board (TB CAB) has developed a ...
ITPCru ceases its participation in the EECA CAB in favor of its own project activities and from now on work of the EECA CAB will be coordinated by the ECUO.
Note that the ECUO and ITPCru which in 2009 jointly initiated establishment of the Community Advisory ...
Conference funders, Gilead Sciences, named and shamed for its “insatiable greed”
9th International AIDS Conference on HIV Science in Paris (IAS 2017), drew to a close, in style. The community address delivered by Othoman Mellouk, during the final ceremony, exposed one of the key conference sponsors, ...
AIDES and PLUS announced to conference attendees from the world over results from the biggest European survey ever to be conducted regarding knowledge, interest and utilisation of PrEP, Flash! PrEP in Europe. This presentation revealed the principal barriers, both individual and structural, regarding access to this ...
PARIS — The last time the International AIDS Society Conference on HIV Science met in 2003, fewer than 2 million people globally were on HIV treatment. As the event returned to Paris this week, UNAIDS reported 19.5 million people are now taking antiretroviral therapy, or ART.
The numbers put ...
In 2015, viral hepatitis caused the death of 1 million 340 thousand people around the world. Such data are published in the report of the World Health Organization, during the International Congress on diseases of the liver ILC 2017 held in Amsterdam.
One of the causes of high mortality is the ...
Extension of 2013 agreement allows an additional 1.4 million people living with HIV to benefit from sublicensed generics of World Health Organization-recommended antiretroviral.
Paris, 25 July 2017 — The Medicines Patent Pool (MPP) has signed an extension of its licensing agreement with biopharmaceutical company Bristol-Myers Squibb ...
AbbVie’s new pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C co-infection in the EXPEDITION-2 study, according to a presentation on Monday at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris.
Glecaprevir/pibrentasvir (Maviret) is expected to be approved ...
HVTN 705 vaccine study passes its “go” criteria: due to start this autumn
A year ago, one of the biggest pieces of prevention news at the Durban International AIDS Conference was the announcement that a large HIV vaccine efficacy study would start in South Africa. HVTN 702, ...
The report published today focuses on the status of current, emerging and potential technologies in TB diagnosis. Many countries still rely on tools such as sputum-smear microscopy but new diagnostics are slowly changing the TB diagnostics landscape.
Tuberculosis (TB) continues to be a major public health ...
23.07.2017 The results from clinical trials are usually discussed within the scientific community only and are seldom spread to the general public.
With the release of the EU Clinical Trials Regulation 536/2014 in 2014, informing the public about clinical trial results will become mandatory in Europe.
Lay ...
WHO today prequalified the first generic version of sofosbuvir, a critical medicine for the treatment of hepatitis C. The development could expand access to treatment by increasing the number of quality-assured generic medicines on the market. Sofosbuvir, 400 mg tablet, is manufactured by Mylan Laboratories ...
A new report released today ahead of the 9th IAS Conference on HIV Science documents 2016 funding and highlights a continuing trend of flat or declining funding and its potential impact on further innovation in HIV prevention research and development (R&D).
The Resource Tracking for HIV Prevention ...